MA56113A - Formes solides de (6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-méthyl-2-oxa-8-azaspiro [4,5]décan-8-yl]-5-méthylpyrazin-2-yl)méthanol, un inhibiteur de shp2 - Google Patents

Formes solides de (6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-méthyl-2-oxa-8-azaspiro [4,5]décan-8-yl]-5-méthylpyrazin-2-yl)méthanol, un inhibiteur de shp2

Info

Publication number
MA56113A
MA56113A MA056113A MA56113A MA56113A MA 56113 A MA56113 A MA 56113A MA 056113 A MA056113 A MA 056113A MA 56113 A MA56113 A MA 56113A MA 56113 A MA56113 A MA 56113A
Authority
MA
Morocco
Prior art keywords
amino
methylpyrazin
decan
azaspiro
chloropyridin
Prior art date
Application number
MA056113A
Other languages
English (en)
French (fr)
Inventor
Steven G Ballmer
Shaoling Li
Original Assignee
Revolution Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revolution Medicines Inc filed Critical Revolution Medicines Inc
Publication of MA56113A publication Critical patent/MA56113A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA056113A 2019-06-07 2020-06-04 Formes solides de (6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-méthyl-2-oxa-8-azaspiro [4,5]décan-8-yl]-5-méthylpyrazin-2-yl)méthanol, un inhibiteur de shp2 MA56113A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962858837P 2019-06-07 2019-06-07

Publications (1)

Publication Number Publication Date
MA56113A true MA56113A (fr) 2022-04-13

Family

ID=71787182

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056113A MA56113A (fr) 2019-06-07 2020-06-04 Formes solides de (6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-méthyl-2-oxa-8-azaspiro [4,5]décan-8-yl]-5-méthylpyrazin-2-yl)méthanol, un inhibiteur de shp2

Country Status (15)

Country Link
US (2) US11220501B2 (cg-RX-API-DMAC7.html)
EP (1) EP3980128A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022534788A (cg-RX-API-DMAC7.html)
KR (1) KR20220019017A (cg-RX-API-DMAC7.html)
CN (2) CN114190090A (cg-RX-API-DMAC7.html)
AU (1) AU2020288631A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021022635A2 (cg-RX-API-DMAC7.html)
CA (1) CA3142430A1 (cg-RX-API-DMAC7.html)
IL (1) IL288568A (cg-RX-API-DMAC7.html)
MA (1) MA56113A (cg-RX-API-DMAC7.html)
MX (1) MX2021014855A (cg-RX-API-DMAC7.html)
PH (1) PH12021552902A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202112461QA (cg-RX-API-DMAC7.html)
TW (1) TW202112785A (cg-RX-API-DMAC7.html)
WO (1) WO2020247643A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI852912B (zh) 2017-09-07 2024-08-21 美商銳新醫藥公司 Shp2抑制劑組合物以及治療癌症的方法
CA3142430A1 (en) 2019-06-07 2020-12-10 Revolution Medicines, Inc. Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor
TW202313041A (zh) 2021-06-09 2023-04-01 瑞士商諾華公司 包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合
TW202317100A (zh) 2021-06-23 2023-05-01 瑞士商諾華公司 包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途
US20240374571A1 (en) 2021-09-01 2024-11-14 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
EP1871762A2 (en) * 2005-04-18 2008-01-02 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
NZ623069A (en) 2009-08-17 2015-11-27 Sloan Kettering Inst Cancer Heat shock protein binding compounds, compositions, and methods for making and using same
JO3517B1 (ar) * 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
ES2699351T3 (es) * 2014-01-17 2019-02-08 Novartis Ag Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
IL311645B2 (en) 2016-07-12 2025-11-01 Revolution Medicines Inc 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors
TWI852912B (zh) 2017-09-07 2024-08-21 美商銳新醫藥公司 Shp2抑制劑組合物以及治療癌症的方法
KR20200143417A (ko) 2018-04-10 2020-12-23 레볼루션 메디슨즈, 인크. Shp2 억제제 조성물, 암을 치료하는 방법 및 shp2 돌연변이를 갖는 대상체를 확인하는 방법
CA3142430A1 (en) 2019-06-07 2020-12-10 Revolution Medicines, Inc. Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor

Also Published As

Publication number Publication date
US12528807B2 (en) 2026-01-20
JP2022534788A (ja) 2022-08-03
TW202112785A (zh) 2021-04-01
MX2021014855A (es) 2022-01-18
CN115141205A (zh) 2022-10-04
EP3980128A1 (en) 2022-04-13
IL288568A (en) 2022-02-01
AU2020288631A1 (en) 2021-12-09
BR112021022635A2 (pt) 2022-01-04
JP2025138706A (ja) 2025-09-25
PH12021552902A1 (en) 2022-04-04
US11220501B2 (en) 2022-01-11
CN114190090A (zh) 2022-03-15
WO2020247643A1 (en) 2020-12-10
KR20220019017A (ko) 2022-02-15
CA3142430A1 (en) 2020-12-10
US20210253574A1 (en) 2021-08-19
SG11202112461QA (en) 2021-12-30
US20220298159A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
IL288568A (en) Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,s4)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5] Decan-8-yl]-5-methylpyrazin-2-yl}methanol as shp2 inhibitors
AU2015293541B2 (en) Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof
PT4058453T (pt) Síntese melhorada de composto inibidor de kras g12c
EP3931351A4 (en) TARGET DETECTION SYSTEMS, COMPOSITIONS AND METHODS
EP3768671A4 (en) SUBSTITUTED IMIDAZOLIDIN-2-ON DERIVATIVES AS PRMT5 INHIBITORS
MX2022005256A (es) Inhibidores de cd73.
EA201691029A1 (ru) Кристаллические формы аналогов противовирусного соединения софосбувира
EP4018583A4 (en) BEAM TRACKING FOR REDUCED LATENCY
EP4309163B1 (en) PEDESTRIAN LOCATION USING TELEMETRY ASSISTANCE
EA202190537A1 (ru) Способ улавливания кислотных сульфидных соединений
EA202091979A1 (ru) Кристаллические формы и способы получения кристаллических форм соединения
DK3784649T3 (da) Fremgangsmåde til syntese af (s)-3-amino-4-(difluormethylenyl)cyclopent-1-en-1-carboxylsyre
EP4043450A4 (en) 2h-benzopyran derivatives as crac inhibitors
IL311670A (en) Resmetirom for reducing liver volume
EP4472627A4 (en) N3-Substituted Uracil Compounds Used as TRPA1 Inhibitors
MA54907A (fr) Inhibiteurs de phosphoinositide 3-kinase topiques
PL4007777T3 (pl) (CAR)T-komórki przeciw BCMA do leczenia szpiczaka mnogiego
EP3996707A4 (en) CRYSTALLINE FORMS OF PLASMACALLICREIN INHIBITORS
EP4198205A4 (en) SYSTEM FOR ADJUSTING THE TARGET TRAVEL OF AN IMPLEMENT
EP3982959A4 (en) NEW SUBSTITUTED TETRAHYDROQUINOLINE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS
HK40072890A (en) Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor
EP3967310A4 (en) QUINOLINE DERIVATIVE USED IN SOFT TISSUE SARCOMBINATION THERAPY
ATE496025T1 (de) Magnesiumsalze von hmg-coa-reduktase-hemmern
EP3930712A4 (en) IMIDAZOLOPYRAZINE COMPOUNDS FOR IRE1 INHIBITION
LT4115879T (lt) Farmacinė kompozicija, apimanti hmg-coa reduktazės inhibitorius ir fenofibratą